Citizens Financial Group Inc. RI Takes $71,000 Position in The Oncology Institute, Inc. (NASDAQ:TOI)

Key Points

• Citizens Financial Group Inc. RI acquired 62,700 shares of The Oncology Institute, Inc. (NASDAQ:TOI), representing a stake worth approximately $71,000.
• A significant number of institutional investors have recently increased their positions in TOI, with 36.86% of the stock currently owned by institutional entities.
• The Oncology Institute reported a quarterly revenue of $104.41 million but posted a loss of ($0.18) EPS and a negative return on equity of 445.02%.

Citizens Financial Group Inc. RI acquired a new stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 62,700 shares of the company's stock, valued at approximately $71,000. Citizens Financial Group Inc. RI owned about 0.08% of Oncology Institute at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares during the period. XTX Topco Ltd raised its position in shares of Oncology Institute by 49.5% in the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after acquiring an additional 18,448 shares during the period. WealthShield Partners LLC purchased a new stake in shares of Oncology Institute during the first quarter worth about $80,000. Finally, Jane Street Group LLC increased its stake in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after purchasing an additional 109,769 shares in the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Oncology Institute

In related news, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the sale, the director directly owned 603,501 shares in the company, valued at $1,732,047.87. This trade represents a 76.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Growth I. L.P. M33 sold 76,324 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director directly owned 1,272,724 shares in the company, valued at $3,881,808.20. The trade was a 5.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,726,137 shares of company stock worth $13,379,013 over the last quarter. 8.50% of the stock is owned by company insiders.

Oncology Institute Stock Down 0.9%

Oncology Institute stock traded down $0.04 during mid-day trading on Monday, reaching $4.24. 1,501,043 shares of the company's stock were exchanged, compared to its average volume of 2,172,185. The company has a market cap of $378.34 million, a P/E ratio of -6.06 and a beta of 0.08. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $4.50. The company has a quick ratio of 1.59, a current ratio of 1.79 and a debt-to-equity ratio of 14.58. The company has a fifty day moving average of $3.02 and a 200-day moving average of $2.15.

Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%. The firm had revenue of $104.41 million during the quarter.

Analysts Set New Price Targets

TOI has been the subject of several research reports. B. Riley initiated coverage on shares of Oncology Institute in a research note on Wednesday, July 16th. They set a "buy" rating and a $6.00 price objective for the company. Noble Financial started coverage on shares of Oncology Institute in a research note on Wednesday, July 23rd. They issued an "outperform" rating and a $8.00 price target for the company. Finally, BTIG Research assumed coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They set a "buy" rating and a $7.00 price objective for the company.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.